Female Sexual Interest/Arousal Disorder
Conditions
Brief summary
The purpose of this study is to evaluate the effectiveness of Libicare® in the sexual desire and arousal at 12 weeks in peri or postmenopausal women aged between 40 and 60 years old with low sexual desire and arousal compared with active control.
Detailed description
The purpose of this study is to evaluate the effectiveness of Libicare® in the sexual desire and arousal at 12 weeks in peri or postmenopausal women aged between 40 and 60 years old with low sexual desire and arousal compared with active control. Despite current consensus in the literature that Female Sexual Dysfunction can manifest at any age in a woman´s life, researchers as Sarrel documented that during menopause, up to 40% of women are experiencing a decrease in their sexual libido. The common assumption is that the menopause contributes to a drop of the sexual desire probably as a result of low production of hormones from ovaries, at the same time will reduce the estrogen and testosterone. This reduction starts to be reduced in the thirties and continues to reduce progressively at a constant rate reaching of about 50% of their initial highest levels by the time they reach menopause. Other hormones could be involved as Sex hormone-binding globulin (SHBG) or dehydroepiandrosterone (DHEA), both are related with testosterone levels. Libicare® is a dietary supplement whose ingredients could have positive effects on the improvement of sexual function in women with low desire and arousal levels.
Interventions
DIETARY_SUPPLEMENTLibicare
The main ingredients of Libicare® are: * Trigonella Foenum-graecum (Trigonella) * Tribulus Terrestris (Tribulus) * Turnera Diffusa (Damiana)
DIETARY_SUPPLEMENTactive control
Selenium and vitamins B complex
Sponsors
Procare Health Iberia S.L.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
The analysis of the results will be blind for the investigator
Intervention model description
The selected patients will be randomly distributed in one of the two arms (Libicare® / active-control), in a 2:1 ratio according to a randomization list. The kits containing the study treatment (Libicare®) and the active-control will be numbered with a randomization code according to this unique list and will be distributed to the consultations. Patients will not know the treatment and only the researchers and team investigator assigned to the study will know the treatment assigned. A second randomization list (ratio 1:1) will be generated for Libicare® responding patients, at 12 weeks in order to assign two sub-groups: continue Libicare® treatment or observation without Libicare® treatment.
Eligibility
Sex/Gender
FEMALE
Age
45 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Female aged between 40 and 60 years old. 2. Healthy peri or postmenopausal women. 3. Body Mass Index (BMI) between 18,5-29,9. 4. Female with low sexual desire and low arousal with a score ≤26.55 on the questionnaire Female Sexual Function Index (FSFI) . 5. Patients who signed the Informed Consent Form.
Exclusion criteria
1. Female with uncontrolled thyroid function. 2. Female with severe genital pain (vaginism, stopping intercourse because of severe pain). 3. Female diagnosed with primary female orgasmic disorder. 4. No coital intercourse a month. 5. Lack of steady sexual partner. 6. Suffering from any serious medical condition (any disease which may force the participant to use drug during the study). 7. Suffering from major depression disorder or other psychiatric disorders. 8. Women on anticoagulant treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evolution of sexual desire and arousal | 12 weeks | The evolution of the composite score from sexual desire and arousal obtained using FSFI (Female Sexual Function Index) questionnaire. It has 19 questions with six domains included desire, arousal, lubrication, orgasm, satisfaction and pain, and a general score in which higher scores reflected better sexual activity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The evolution of the FSFI questionnaire total score | at 6, 12 and 24 weeks | The evolution of the FSFI (Female Sexual Function Index) questionnaire total score. Composite score from sexual desire and arousal domains will be calculed as the sum of desire items (2 questions) and arousal items (4 questions). Higher scores reflected better sexual activity. |
| The evolution of other each sexual FSFI domain score | at 6, 12 and 24 weeks | The evolution of other each sexual FSFI domain score (Female Sexual Function Index) It contains 2 questions of desire domain and 4 questions of arousal domain. Higher scores reflected better sexual activity. |
| To evaluate the hormonal levels (free testosterone and SHBG) | at 6, 12 and 24 weeks | changes in hormonals levels |
| The evolution of the vitality status obtained using the Subjective Vitality Scale questionnaire | at 12 and 24 weeks | The evolution of the vitality scale (an 7-point Likert Scale) contains 7 items. Higher scores reflected better vitality status. |
| The improvement in the Quality of life of women by EQ-5D-5L questionnaire | at 12 and 24 weeks | The improvement in the Quality of life of women by EQ-5D-5L (European Quality of Life-5 Dimensions) questionnaire. It comprises the same 5 dimensions (mobility, self care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The result is in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. |
| The evolution of the composite score from sexual desire and arousal | at 6 and 24 weeks | The evolution of the composite score from sexual desire and arousal obtained using FSFI (Female Sexual Function Index) questionnaire. It has 19 questions with six domains included desire, arousal, lubrication, orgasm, satisfaction and pain, and a general score in which higher scores reflected better sexual activity. |
| The improvement of is frequency of intercourse and non-intercourse activity (total and satisfying events), number of orgasms using the SAL© | at 6, 12 and 24 weeks | The improvement of is frequency of intercourse and non-intercourse activity (total and satisfying events), number of orgasms using the SAL© ((Sexual Activity Log©). It is a weekly diary that it measures frequency of intercourse and non-intercourse activity (total and satisfying events), number of orgasms. |
| The evaluation of the degree of therapeutic compliance | at 6, 12 and 24 weeks | The evaluation of the degree of therapeutic compliance throught Likert Scale of 5 points (from 1 = Very satisfied to 5 = Very dissatisfied) will be analysed by means of percentage. |
| Adverse events and adverse drug reactions | at 6, 12 and 24 weeks. | To evaluate the safety of libicare measuring the incidence and duration of adverse events and adverse drug reactions. |
| Weight, height and BMI | at baseline, 6, 12 and 24 weeks | Safety endpoint for evaluating weigh and BMI (body mass index) changes. |
| Clinical satisfaction of the women with the treatment, using a Likert-type scale | at 6, 12 and 24 weeks | Clinical satisfaction of the women with the treatment, using a Likert-type scale of 7 points (from 1 = Very satisfied to 7 = Very dissatisfied) |
Countries
Spain
Outcome results
None listed